AstraZeneca Invests $1.5 Billion to Construct Antibody Drug Conjugate Facility in Singapore
Introduction:
AstraZeneca has announced a significant investment of $1.5 billion to establish a state-of-the-art manufacturing facility in Singapore, dedicated to the production of Antibody-Drug Conjugates (ADCs). This facility will play a pivotal role in advancing the company’s efforts to deliver cutting-edge cancer treatments
Features:
AstraZeneca's new facility is dedicated to producing Antibody-Drug Conjugates (ADCs) designed to precisely target cancer cells, ensuring the global supply of next-generation treatments.
The company boasts an extensive portfolio of in-house ADCs, including six currently in clinical trials and numerous others in preclinical development.
AstraZeneca unveiled encouraging data highlighting the potential of its proprietary ADC technology in treating various cancers, such as breast, endometrial, and ovarian cancers.
The new construction facility will handle complex multi-step ADC production, including antibody creation, drug-linker synthesis, conjugation, and final product filling.
The new facility will also create over 800 jobs, focusing on skilled professionals in engineering, quality assurance, technical services, and global supply chain management.
AstraZeneca's commitment to expanding its capabilities in the global fight against cancer, particularly through targeted therapies that use ADCs to deliver potent anti-cancer agents directly to malignant cells.
The construction will be commenced by 2029.
Specifications:
| Name : | AstraZeneca |
| Type : | Construction |
| Budget : | $1.5 Billion |
| Year : | 2029 |
